Mass spectrometry‐based absolute quantification of microsomal cytochrome P450 2D6 in human liver

We describe the assay of the human cytochrome P450 2D6 in a set of 30 genotyped liver samples using the ‘absolute quantification’ (AQUA) technique. We found approximately 30 fmol CYP2D6 per μg of microsomal protein, with the values spanning from 0 to nearly 80 fmol/μg. This is greater by a factor of 5–10 from the compared to the currently accepted value, which was around 5 fmol/μg. Our results thus suggest that the amount of cytochrome P450 (CYP) enzymes in liver have to be reassessed. We used quantitative Western blotting, calibration standards and activity assays, to validate the results. Our results show, that using the AQUA technique a true assay of CYP2D6 in human liver was possible.

[1]  A. Lender,et al.  Design and synthesis of sulfur-free cyclic hexapeptides which contain the RGD sequence and bind to the fibrinogen GP IIb/IIIa receptor. A conformation-based correlation between propensity for imide formation and receptor affinity. , 2009, International journal of peptide and protein research.

[2]  S. Clarke.  Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. , 2009, International journal of peptide and protein research.

[3]  M. Alterman,et al.  Utility of polyclonal antibodies targeted toward unique tryptic peptides in the proteomic analysis of cytochrome P450 isozymes. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[4]  R. Krämer,et al.  Nuclease and peptidase models , 2008 .

[5]  F. Vandenesch,et al.  Isotope-labeled Protein Standards , 2007, Molecular & Cellular Proteomics.

[6]  Xiaoyan Chen,et al.  Precolumn derivatization of cysteine residues for quantitative analysis of five major cytochrome P450 isoenzymes by liquid chromatography/tandem mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.

[7]  R. Beynon,et al.  Absolute Multiplexed Quantitative Analysis of Protein Expression during Muscle Development Using QconCAT* , 2007, Molecular & Cellular Proteomics.

[8]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[9]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[10]  W. Griffiths,et al.  Proteomic analysis of cytochromes P450: a mass spectrometry approach. , 2006, Biochemical Society transactions.

[11]  M. Eichelbaum,et al.  Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events , 2006, Pharmacogenetics and genomics.

[12]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[13]  Rod B. Watson,et al.  Relative and absolute quantitative expression profiling of cytochromes P450 using isotope‐coded affinity tags , 2006, Proteomics.

[14]  Kelvin H Lee,et al.  Kinetic characterization of sequencing grade modified trypsin , 2005, Proteomics.

[15]  D. Lewis,et al.  57 varieties: the human cytochromes P450. , 2004, Pharmacogenomics.

[16]  C. Bunse,et al.  A peptide preconcentration approach for nano‐high‐performance liquid chromatography to diminish memory effects , 2004, Proteomics.

[17]  A. Shevchenko,et al.  Absolute quantification of proteins in solutions and in polyacrylamide gels by mass spectrometry. , 2004, Analytical chemistry.

[18]  S. Gygi,et al.  Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Mann,et al.  Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). , 2003, Journal of proteome research.

[20]  A. Shevchenko,et al.  Fast-response proteomics by accelerated in-gel digestion of proteins. , 2003, Analytical chemistry.

[21]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.

[22]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[23]  P. Righetti,et al.  Alkylation kinetics of proteins in preparation for two‐dimensional maps: A matrix assisted laser desorption/ionization‐mass spectrometry investigation , 2001, Electrophoresis.

[24]  M. Eichelbaum,et al.  Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[25]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[26]  H. Hauri,et al.  Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Moeremans,et al.  Sensitive colloidal metal (gold or silver) staining of protein blots on nitrocellulose membranes. , 1985, Analytical biochemistry.

[28]  J. Kyhse-Andersen.  Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. , 1984, Journal of biochemical and biophysical methods.

[29]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[30]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[31]  A. Daly.  Significance of the Minor Cytochrome P450 3A Isoforms , 2006, Clinical pharmacokinetics.

[32]  Magnus Ingelman-Sundberg,et al.  Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[33]  E. Dratz,et al.  Absolute quantification of the G protein-coupled receptor rhodopsin by LC/MS/MS using proteolysis product peptides and synthetic peptide standards. , 2003, Analytical chemistry.

[34]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[35]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[36]  Gapped BLAST and PSI-BLAST: A new , 1997 .

[37]  C. Crespi.  Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .

[38]  U. Zanger.  Immunoisolation of human microsomal cytochromes P450 using autoantibodies. , 1991, Methods in enzymology.